Drug Profile
Anakinra - Swedish Orphan Biovitrum
Alternative Names: 143090-92-0; Antril; Kinaret; Kineret; Recombinant human interleukin-1 receptor antagonist; rhIL-1ra; rIL-1ra; rIL1RNLatest Information Update: 18 Mar 2024
Price :
$50
*
At a glance
- Originator Amgen
- Developer Amgen; CHRU de Tours; Swedish Orphan Biovitrum
- Class Anti-infectives; Anti-inflammatories; Antibacterials; Antigouts; Antineoplastics; Antirheumatics; Recombinant proteins
- Mechanism of Action Interleukin 1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Cryopyrin-associated periodic syndromes; Rheumatoid arthritis
- Registered Adult-onset Still's disease; Autoimmune disorders; COVID-19 pneumonia; Familial Mediterranean fever; Juvenile rheumatoid arthritis
- Phase III COVID 2019 infections
- Phase II Gout; Non-Hodgkin's lymphoma
- Discontinued Ankylosing spondylitis; Graft-versus-host disease; Osteoarthritis; Pneumococcal infections; Septic shock
Most Recent Events
- 31 Oct 2023 Kite completes a phase II clinical trial in Non-Hodgkin's lymphoma (Combination therapy, Second-line therapy or greater) in USA (SC) (NCT04150913)
- 22 Aug 2023 Preregistration for Cryopyrin-associated periodic syndromes in China (SC) (Swedish Orphan Biovitrum pipeline, August 2023)
- 10 Nov 2022 Registered (emergency use authorization) for COVID-19 pneumonia in USA (SC)